From the Research
Intravenous (IV) NAD+ administration provides 100% bioavailability, whereas subcutaneous (SC) NAD+ administration has a lower bioavailability, typically around 70-80%. This difference in bioavailability is due to the fact that IV administration delivers the compound directly into the bloodstream, bypassing first-pass metabolism, while SC administration requires absorption through tissues before entering circulation 1.
Key Considerations
- IV administration produces immediate peak blood levels and effects, while SC delivery creates a more gradual absorption profile with a delayed peak and longer duration of action.
- The subcutaneous route may cause local irritation at the injection site but generally has a lower risk of systemic adverse reactions compared to IV administration.
- For most clinical applications requiring rapid effects or precise dosing, IV administration is preferred, while SC delivery may be more suitable for situations requiring sustained release or when IV access is challenging.
Patient Preference and Quality of Life
- Studies have shown that patients often prefer SC administration due to its convenience, time-saving, and ability to have treatment at home 1.
- Patient preference is an important factor in medical decision-making, as it can impact treatment adherence and quality of life.
Administration Factors
- The choice between IV and SC administration should consider the urgency of treatment, desired pharmacokinetic profile, patient comfort, and practical administration factors.
- The typical dosing range for NAD+ therapy is 500-1500mg, with IV infusions usually administered over 1-3 hours to minimize side effects like flushing and nausea.
Evidence Summary
- While multiple studies support the differences in bioavailability and administration profiles between IV and SC NAD+ administration, the most recent and highest-quality study 1 emphasizes the importance of patient preference in choosing the administration route.